$DXCM
DEXCOM INC Stock $dxcm

$dxcm Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000109355718000084 Filed on May 02, 2018

Income Statement

Concept	2018 Q1	2017 Q1
Revenue	$184.4M	$142.3M
YoY Change	29.59%	22.46%
Cost Of Revenue	$65.50M	$48.20M
YoY Change	35.89%	17.27%
Gross Profit	$118.9M	$94.10M
YoY Change	26.35%	25.3%
Gross Profit Margin	64.48%	66.13%
Selling, General & Admin	$104.8M	$86.40M
YoY Change	21.3%	39.13%
% of Gross Profit	88.14%	91.82%
Research & Development	$44.80M	$48.10M
YoY Change	-6.86%	49.38%
% of Gross Profit	37.68%	51.12%
Depreciation & Amortization	$6.000M	$3.700M
YoY Change	62.16%	8.82%
% of Gross Profit	5.05%	3.93%
Operating Expenses	$149.6M	$134.5M
YoY Change	11.23%	42.63%
Operating Profit	-$30.70M	-$40.40M
YoY Change	-24.01%	110.42%
Interest Expense	$4.800M	$500.0K
YoY Change	860.0%	400.0%
% of Operating Profit
Other Income/Expense, Net	$2.600M	$400.0K
YoY Change	550.0%
Pretax Income	-$24.00M	-$40.30M
YoY Change	-40.45%	109.9%
Income Tax	$200.0K	$1.400M
% Of Pretax Income
Net Earnings	-$24.20M	-$41.70M
YoY Change	-41.97%	117.19%
Net Earnings / Revenue	-13.12%	-29.3%
Basic Earnings Per Share	-$0.28	-$0.49
Diluted Earnings Per Share	-$0.28	-$0.49
COMMON SHARES
Basic Shares Outstanding	87.00M shares	84.82M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$521.5M	$181.1M
YoY Change	187.96%	70.05%
Cash & Equivalents	$420.4M	$153.5M
Short-Term Investments	$101.1M	$27.60M
Other Short-Term Assets	$19.90M	$17.00M
YoY Change	17.06%	126.67%
Inventory	$51.60M	$46.50M
Prepaid Expenses
Receivables	$123.9M	$85.90M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$729.3M	$330.5M
YoY Change	120.67%	45.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$152.4M	$123.4M
YoY Change	23.5%	87.25%
Goodwill	$12.30M	$11.40M
YoY Change	7.89%	208.11%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.800M	$1.900M
YoY Change	47.37%	375.0%
Total Long-Term Assets	$167.5M	$136.7M
YoY Change	22.53%	89.86%
TOTAL ASSETS
Total Short-Term Assets	$729.3M	$330.5M
Total Long-Term Assets	$167.5M	$136.7M
Total Assets	$896.8M	$467.2M
YoY Change	91.95%	56.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$38.90M	$17.90M
YoY Change	117.32%	-16.74%
Accrued Expenses	$83.30M	$77.60M
YoY Change	7.35%	92.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$75.00M
YoY Change	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$125.1M	$171.7M
YoY Change	-27.14%	167.86%
LONG-TERM LIABILITIES
Long-Term Debt	$338.7M	$6.700M
YoY Change	4955.22%
Other Long-Term Liabilities	$18.70M	$17.70M
YoY Change	5.65%	331.71%
Total Long-Term Liabilities	$18.70M	$17.70M
YoY Change	5.65%	331.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$125.1M	$171.7M
Total Long-Term Liabilities	$18.70M	$17.70M
Total Liabilities	$475.1M	$189.4M
YoY Change	150.84%	177.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$696.0M	-$663.3M
YoY Change	4.93%	15.44%
Common Stock	$1.123B	$942.3M
YoY Change	19.12%	16.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$421.7M	$277.8M
YoY Change
Total Liabilities & Shareholders Equity	$896.8M	$467.2M
YoY Change	91.95%	56.05%

Cashflow Statement

Concept	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$24.20M	-$41.70M
YoY Change	-41.97%	117.19%
Depreciation, Depletion And Amortization	$6.000M	$3.700M
YoY Change	62.16%	8.82%
Cash From Operating Activities	-$8.700M	$300.0K
YoY Change	-3000.0%	-250.0%
INVESTING ACTIVITIES
Capital Expenditures	$15.30M	$22.90M
YoY Change	-33.19%	99.13%
Acquisitions
YoY Change
Other Investing Activities	-$100.0K	$1.500M
YoY Change	-106.67%	400.0%
Cash From Investing Activities	-$15.40M	-$21.40M
YoY Change	-28.04%	91.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$4.200M	$5.300M
YoY Change	-20.75%	39.47%
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	$4.200M	$80.30M
YoY Change	-94.77%	2409.38%
NET CHANGE
Cash From Operating Activities	-$8.700M	$300.0K
Cash From Investing Activities	-$15.40M	-$21.40M
Cash From Financing Activities	$4.200M	$80.30M
Net Change In Cash	-$20.80M	$59.00M
YoY Change	-135.25%	-819.51%
FREE CASH FLOW
Cash From Operating Activities	-$8.700M	$300.0K
Capital Expenditures	$15.30M	$22.90M
Free Cash Flow	-$24.00M	-$22.60M
YoY Change	6.19%	93.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001093557
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	88084933	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	DEXCOM INC
CY2018Q1	dei	Trading Symbol TradingSymbol	DXCM
CY2017Q4	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	7100000	USD
CY2018Q1	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	8800000	USD
CY2017Q4	dxcm	Debt Instrument Current Value Upon Conversion DebtInstrumentCurrentValueUponConversion	0	USD
CY2018Q1	dxcm	Debt Instrument Current Value Upon Conversion DebtInstrumentCurrentValueUponConversion	1900000	USD
CY2018Q1	dxcm	Fair Value Assets Level3 Transfers Amount FairValueAssetsLevel3TransfersAmount	0	USD
CY2017Q4	dxcm	Financing Lease Obligation FinancingLeaseObligation	6700000	USD
CY2018Q1	dxcm	Financing Lease Obligation FinancingLeaseObligation	7400000	USD
CY2017Q4	dxcm	Pharmacy Rebates PharmacyRebates	13900000	USD
CY2018Q1	dxcm	Pharmacy Rebates PharmacyRebates	16000000	USD
CY2018Q1	dxcm	Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm	P1Y
CY2018Q1	dxcm	Revenue Recognition Sales Returns Coverage Period RevenueRecognitionSalesReturnsCoveragePeriod	P30D
CY2017Q1	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	5000000	USD
CY2018Q1	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	4500000	USD
CY2017Q4	dxcm	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense	105700000	USD
CY2017Q4	dxcm	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Transition Tax For Accumulated Foreign Earnings Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpense	0	USD
CY2018Q1	dxcm	Working Capital WorkingCapital	604200000	USD
CY2017Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	87200000	USD
CY2018Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	88000000	USD
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	46700000	USD
CY2018Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	38900000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	134300000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	123900000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	54800000	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	58900000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2600000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4900000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1093700000	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1122500000	USD
CY2017Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	100000	USD
CY2018Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3700000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3600000	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7500000	shares
CY2017Q4	us-gaap	Assets Assets	904100000	USD
CY2018Q1	us-gaap	Assets Assets	896800000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	744700000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	729300000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	200000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	101300000	USD
CY2017Q1	us-gaap	Available For Sale Equity Securities Gross Unrealized Gain AvailableForSaleEquitySecuritiesGrossUnrealizedGain	0	USD
CY2018Q1	us-gaap	Available For Sale Equity Securities Gross Unrealized Gain AvailableForSaleEquitySecuritiesGrossUnrealizedGain	7400000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	107100000	USD
CY2018Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	113500000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7400000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	200000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	200000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	107300000	USD
CY2018Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	106300000	USD
CY2018Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	99600000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	101100000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	107100000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	101100000	USD
CY2018Q1	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	1500000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	153500000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	441500000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	420400000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	533900000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94500000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153500000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	441500000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	420700000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	59000000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20800000	USD
CY2017Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	344600000	USD
CY2018Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	321900000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87300000	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88400000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87000000	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	88100000	shares
CY2017Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2018Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42000000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26500000	USD
CY2017Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	381300000	USD
CY2018Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	415700000	USD
CY2017Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	327600000	USD
CY2018Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	331300000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	48200000	USD
CY2018Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	65500000	USD
CY2017Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	400000000	USD
CY2018Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	400000000	USD
CY2017Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P6M
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	64400000	USD
CY2018Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	61100000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8700000	USD
CY2018Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8500000	USD
CY2017Q4	us-gaap	Deferred Revenue DeferredRevenue	1500000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3200000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2900000	USD
CY2018Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	1500000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3700000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6000000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-200000	USD
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-900000	USD
CY2017Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.03
CY2018Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.01
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	48500000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	34200000	USD
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	193300000	USD
CY2018Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2017Q4	us-gaap	Foreign Earnings Repatriated ForeignEarningsRepatriated	41200000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	12100000	USD
CY2018Q1	us-gaap	Goodwill Goodwill	12300000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	94100000	USD
CY2018Q1	us-gaap	Gross Profit GrossProfit	118900000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40300000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24000000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1400000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2100000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2200000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-15800000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-10700000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	200000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-300000	USD
CY2017Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3300000	USD
CY2018Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-14400000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1000000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6400000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	1200000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	400000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7700000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2700000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	500000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	4800000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	17000000	USD
CY2018Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	19700000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	45200000	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	51600000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	20000000	USD
CY2018Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	22900000	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8200000	USD
CY2018Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9000000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	200000	USD
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1500000	USD
CY2017Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2800000	USD
CY2018Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2800000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	484700000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	475100000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	904100000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	896800000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	138900000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	125100000	USD
CY2018Q1	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	195600000	USD
CY2018Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	0	USD
CY2018Q1	us-gaap	Litigation Reserve LitigationReserve	0	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80300000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4200000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21400000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15400000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	300000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8700000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-41700000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-24200000	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	5600000	USD
CY2018Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	4300000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	134500000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	149600000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-40400000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-30700000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	54900000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	3700000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	11700000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	11400000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	11000000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	9400000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	7700000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10700000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	15400000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1700000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2800000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-300000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2300000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18200000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18700000	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-300000	USD
CY2018Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	900000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	400000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2600000	USD
CY2017Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	2800000	USD
CY2018Q1	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	2800000	USD
CY2018Q1	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-3600000	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	7400000	USD
CY2018Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	32000000	USD
CY2017Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	USD
CY2018Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	1000000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22900000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15300000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2018Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16600000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19900000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5300000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4200000	USD
CY2017Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	75000000	USD
CY2017Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	75000000	USD
CY2018Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	8900000	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	32900000	USD
CY2017Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	4900000	USD
CY2018Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	4400000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	200400000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	211300000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	145600000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	152400000	USD
CY2018Q1	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	81200000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48100000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44800000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	300000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-671800000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-696000000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	184400000	USD
CY2017Q1	us-gaap	Revenues Revenues	142300000	USD
CY2018Q1	us-gaap	Revenues Revenues	184400000	USD
CY2018Q1	us-gaap	Self Insurance Reserve SelfInsuranceReserve	2100000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86400000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	104800000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	30600000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	24600000	USD
CY2016Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	9800000	USD
CY2017Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	9900000	USD
CY2017Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	8800000	USD
CY2018Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	8900000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	419400000	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	421700000	USD
CY2017Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	8000000	USD
CY2018Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	7600000	USD
CY2017Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2018Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	7400000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85200000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87300000	shares
CY2018Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DexCom, Inc. is a medical device company focused on the design, development and commercialization of</font><font style="font-family:inherit;font-size:10pt;"> continuous glucose monitoring (“CGM”)</font><font style="font-family:inherit;font-size:10pt;"> systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of people with diabetes. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “DexCom” refer to DexCom, Inc. and its subsidiaries.</font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with </font><font style="font-family:inherit;font-size:10pt;">U.S. GAAP</font><font style="font-family:inherit;font-size:10pt;"> requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates include excess or obsolete inventories, valuation of inventory, warranty accruals, convertible debt, employee bonus, clinical trial expenses, allowance for bad debt, refunds, rebates, including pharmacy rebates and self-funded insurance liabilities. </font></div></div>

Files In Submission

Name	View Source	Status
0001093557-18-000084-index-headers.html	Edgar Link	pending
0001093557-18-000084-index.html	Edgar Link	pending
0001093557-18-000084.txt	Edgar Link	pending
0001093557-18-000084-xbrl.zip	Edgar Link	pending
dxcm-20180331.xml	Edgar Link	completed
dxcm-20180331.xsd	Edgar Link	pending
dxcm-20180331_cal.xml	Edgar Link	unprocessable
dxcm-20180331_def.xml	Edgar Link	unprocessable
dxcm-20180331_lab.xml	Edgar Link	unprocessable
dxcm-20180331_pre.xml	Edgar Link	unprocessable
dxcm-33118x10q.htm	Edgar Link	pending
dxcm3312018exhibit3101.htm	Edgar Link	pending
dxcm3312018exhibit3102.htm	Edgar Link	pending
dxcm3312018exhibit3201.htm	Edgar Link	pending
dxcm3312018exhibit3202.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DXCM
DEXCOM INC Stock $dxcm

2018 Q1 Form 10-Q Financial Statement

#000109355718000084 Filed on May 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM DEXCOM INC Stock $dxcm

2018 Q1 Form 10-Q Financial Statement

#000109355718000084 Filed on May 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM
DEXCOM INC Stock $dxcm